GH Research Ireland Limited

Psychiatry and Depressive Disorders

GH Research Ireland Limited focuses on treatment-resistant depression, with research centered on patients whose depressive symptoms remain difficult to manage despite standard care. The clinical interest lies in improving outcomes for this severe and persistent form of major depressive disorder.

  • Treatment-resistant depression
  • Depressive symptom reduction
  • Mood disorder management

The sponsor’s research activity in this area reflects a focused therapeutic commitment to mental health and the development of interventions for difficult-to-treat depressive illness.

Clinical Innovation in Psychiatric Care

The funded trial landscape includes evaluation of a novel treatment approach for depression, with attention to symptom improvement and patient response in a controlled clinical setting. This places the sponsor within the broader field of psychiatric therapeutics.

  • Novel depression therapies
  • Symptom assessment
  • Patient response in psychiatry

Its research interest is concentrated on advancing options for individuals with limited treatment alternatives in psychiatric medicine.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects of Mebufotenin (GH001) for Patients with Treatment-Resistant Depression

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Ireland Poland Spain